Generic Semaglutide Coming to Market
PharmaGiant.com announced plans to expand its catalog of affordable medications, including an upcoming generic version of semaglutide. Semaglutide is the active ingredient in popular and costly diabetes and weight-management drugs. The move aims to address rising prescription drug costs in the U.S. and increase patient access.
The active ingredient, semaglutide, is at the center of a global patent battle. While patents in countries like China, India, and Canada are set to expire in 2026, Novo Nordisk's key patents in the U.S. don't expire until 2032. This difference in patent timelines is why generic versions are expected in some parts of the world long before they are available in the United States. In the U.S., the list price for a month's supply of Wegovy is approximately $1,349, and for Ozempic, it's around $1,028. Novo Nordisk has announced plans to lower these list prices by up to 50% starting in January 2027. The prospect of more affordable options has numerous pharmaceutical companies preparing to enter the market. In India alone, at least six or seven drugmakers, including Sun Pharma, Dr. Reddy's Laboratories, and Natco Pharma, are getting ready to launch their generic versions. This influx of competition is expected to drive prices down significantly. Globally, the competition is even broader. In China, at least 15 companies are developing generic semaglutide, with many already in the final stages of clinical trials. This surge in manufacturing is anticipated to dramatically increase the global supply of the medication. Before any generic drug can be sold in the U.S., it must go through the Food and Drug Administration's Abbreviated New Drug Application (ANDA) process. This process requires manufacturers to prove their generic version is pharmaceutically equivalent and bioequivalent to the brand-name drug, ensuring it is just as safe and effective.
